To amend title VIII of the Defense Production Act of 1950 to alter the definitions of "prohibited technology" and "notifiable technology", and for other purposes.

[Congressional Bills 119th Congress] [From the U.S. Government Publishing Office] [H.R. 9102 Introduced in House (IH)] <DOC> 119th CONGRESS 2d Session H. R. 9102 To amend title VIII of the Defense Production Act of 1950 to alter the definitions of ``prohibited technology'' and ``notifiable technology'', and for other purposes. _______________________________________________________________________ IN THE HOUSE OF REPRESENTATIVES June 2, 2026 Mr. Moolenaar (for himself and Mrs. Dingell) introduced the following bill; which was referred to the Committee on Financial Services _______________________________________________________________________ A BILL To amend title VIII of the Defense Production Act of 1950 to alter the definitions of ``prohibited technology'' and ``notifiable technology'', and for other purposes. Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled, SECTION 1. SHORT TITLE. This Act may be cited at the ``Biotech Investment National Security Act of 2026'' or the ``BINSA Act''. SEC. 2. FINDINGS. The Congress finds the following: (1) China has pursued a deliberate, state-directed strategy to dominate global biotechnology, including pharmaceutical development, biologics manufacturing, and clinical research and development capabilities. (2) United States capital flowing to Chinese biotechnology companies through licensing agreements, joint ventures, and equity investments is accelerating China's acquisition of pharmaceutical intellectual property and clinical development capabilities in a manner that creates strategic dependency risks for the United States. (3) Cross-border out-licensing transactions between United States and European pharmaceutical companies and Chinese biotechnology firms totaled approximately $136,000,000,000 in 2025, representing a rapid and accelerating transfer of pharmaceutical innovation capacity to entities subject to the direction and control of the People's Republic of